Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer Research

• Publication date

  2015-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-14-2852PMID 25878147PMCID PMC6773609
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• European cancer mortality predictions for the year 2014.

  2014cited by this paper
• Are mast cells instrumental for fibrotic diseases?

  2014cited by this paper
• Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.

  2014cited by this paper
• Beyond allergy: the role of mast cells in fibrosis.

  2014cited by this paper
• Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer.

  2013influential reference
• European cancer mortality predictions for the year 2013.

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice

  2013cited by this paper
• European cancer mortality predictions for the year 2012.

  2012cited by this paper
• Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma

  2011influential reference
• Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma.

  2011cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

  2011cited by this paper
• Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma.

  2011cited by this paper
• Crosstalk between Mast Cells and Pancreatic Cancer Cells Contributes to Pancreatic Tumor Progression

  2010cited by this paper
• Interleukin‐6 acts in the fashion of a classical chemokine on monocytic cells by inducing integrin activation, cell adhesion, actin polymerization, chemotaxis, and transmigration

  2008cited by this paper
• The controversial role of tumor necrosis factor alpha in fibrotic diseases.

  2008cited by this paper
• Analysis of mortality rates for pancreatic cancer across the world.

  2008cited by this paper
• Decreasing TNF-alpha results in less fibrosis and earlier resolution of granulomatous experimental autoimmune thyroiditis.

  2007cited by this paper
• Tumor-stroma interactions in pancreatic ductal adenocarcinoma

  2007cited by this paper
• Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors

  2007cited by this paper
• Decreasing TNF‐α results in less fibrosis and earlier resolution of granulomatous experimental autoimmune thyroiditis

  2007cited by this paper
• Diminished induction of skin fibrosis in mice with MCP-1 deficiency.

  2006cited by this paper
• Soluble TNF Mediates the Transition from Pulmonary Inflammation to Fibrosis

  2006cited by this paper
• Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.

  2006cited by this paper
• Liver fibrosis.

  2005cited by this paper
• Temporal dissection of p53 function in vitro and in vivo

  2005cited by this paper
• Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

  2005cited by this paper
• Erratum: Liver fibrosis (Journal of Clinical Investigation (2005) 115 (209-218) DOI:10.1172/JCI200524282)

  2005cited by this paper
• Association of Serum Interleukin-8 Levels with the Degree of Fibrosis in Infants with Chronic Liver Disease

  2004cited by this paper
• Liver fibrosis

  2004cited by this paper
• Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

  2003cited by this paper
• Food Intake, Water Intake, and Drinking Spout Side Preference of 28 Mouse Strains

  2002cited by this paper
• Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors.

  2002cited by this paper
• Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

  2001cited by this paper
• Pancreatic tumors show high levels of hypoxia.

  2000cited by this paper
• Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity.

  1998cited by this paper
• Role of MCP‐1 and RANTES in inflammation and progression to fibrosis during murine crescentic nephritis

  1997cited by this paper
• Diagnostic Criteria for Chronic Pancreatitis by the Japan Pancreas Society

  1997cited by this paper
• Asthma, mast cells, and sodium cromoglycate.

  1983cited by this paper
• NEGATIVE SYNACTHEN TEST DURING ETOMIDATE INFUSION

  1983cited by this paper

• Targeting stromal components in pancreatic ductal adenocarcinoma: a review

  2025cites this paper
• Improving Outcomes in Pancreatic Adenocarcinoma: A Systematic Review of Immunotherapy in Multimodal Treatment

  2025cites this paper
• Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor.

  2024cites this paper
• The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers.

  2024cites this paper
• Current trends and future prospects of drug repositioning in gastrointestinal oncology

  2024cites this paper
• Nanoformulation of dasatinib cannot overcome therapy resistance of pancreatic cancer cells with low LYN kinase expression

  2024cites this paper
• Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment

  2023cites this paper
• Immune cells and immune cell-targeted therapy in chronic pancreatitis

  2023cites this paper
• Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

  2023cites this paper
• Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study

  2023cites this paper
• The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook

  2023cites this paper
• Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation

  2023cites this paper
• N6-methyladenosine modification of FZR1 mRNA promotes gemcitabine resistance in pancreatic cancer.

  2023cites this paper
• Zanubrutinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β1 signaling pathway.

  2022cites this paper
• Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma

  2022cites this paper
• Focus on mast cells in the tumor microenvironment: Current knowledge and future directions.

  2022cites this paper
• Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer

  2022cites this paper
• Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies

  2022cites this paper
• Focal adhesion kinase priming in pancreatic cancer, altering biomechanics to improve chemotherapy

  2022cites this paper
• Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot

  2022cites this paper
• Personalized tumor vaccine for pancreatic cancer

  2022cites this paper
• Ibrutinib attenuated DSS-induced ulcerative colitis, oxidative stress, and the inflammatory cascade by modulating the PI3K/Akt and JNK/NF-κB pathways

  2022cites this paper
• Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions

  2022influential citation
• B-Lymphocytes in the Pathophysiology of Pancreatic Adenocarcinoma

  2022cites this paper
• Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study

  2021influential citation
• Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment

  2021cites this paper
• Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma

  2021influential citation
• Ibrutinib in Combination with Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma: Phase 3 RESOLVE Study.

  2021cites this paper
• Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.

  2021cites this paper
• Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer

  2021cites this paper
• Emerging Treatment Strategies in Pancreatic Cancer

  2021cites this paper
• Therapeutic targets in the pancreatic adenocarcinoma microenvironment: past challenges and opportunities for the future

  2021cites this paper
• Targeting the Stroma in the Management of Pancreatic Cancer

  2021cites this paper
• Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes

  2021cites this paper
• Inhibition of TRIM32 by ibr‐7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway

  2021cites this paper
• The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies

  2021cites this paper
• Targeting Solid Tumors With BTK Inhibitors

  2021cites this paper
• Therapeutic resistance of pancreatic cancer: Roadmap to its reversal.

  2020cites this paper
• Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition

  2020cites this paper
• Turning liabilities into opportunities: Off-target based drug repurposing in cancer.

  2020cites this paper
• The effect of ibrutinib on radiosensitivity in pancreatic cancer cells by targeting EGFR/AKT/mTOR signaling pathway.

  2020cites this paper
• Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

  2020cites this paper
• CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers

  2020cites this paper
• Targeting the immune milieu in gastrointestinal cancers

  2020cites this paper
• Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma

  2019cites this paper
• Updates in pancreatic cancer: Modest gains and hopeful targets

  2019cites this paper
• New roles for B cell receptor associated kinases: when the B cell is not the target

  2019cites this paper
• Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma

  2019cites this paper
• Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment

  2019cites this paper
• The platelet NLRP3 inflammasome is upregulated in a murine model of pancreatic cancer and promotes platelet aggregation and tumor growth

  2019cites this paper
• Dual-Ligand Modification of PEGylated Liposomes Used for Targeted Doxorubicin Delivery to Enhance Anticancer Efficacy

  2019cites this paper
• A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors

  2019cites this paper
• Unraveling the syndrome of the age-associated diseases : Cancer , Cardiovascular , and Neurological disorders . Common pathways and novel therapeutic strategies

  2019cites this paper
• Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma

  2019cites this paper
• From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer

  2019cites this paper
• Evolving trends in pancreatic cancer therapeutic development.

  2019cites this paper
• New therapeutic targets in pancreatic cancer.

  2019cites this paper
• Mast Cells as a Double Edged Sword in Immunity: Their Function in Health and Disease. First of Two Parts.

  2019cites this paper
• Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL

  2019cites this paper
• Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner

  2018cites this paper
• BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC

  2018cites this paper
• Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies

  2018influential citation
• Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer?

  2018cites this paper
• Novel Approaches For The Identification And Targeted Clearance Of Senescent Cells, As A Therapeutic Strategy For Senescence-Related And Age-Related Diseases

  2018cites this paper
• Inhibition of platelet-tumour cell interaction with ibrutinib reduces proliferation, migration and invasion of lung cancer cells

  2018cites this paper
• Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response.

  2018cites this paper
• To Help or To Harm

  2018cites this paper
• Targeting tumour microenvironment by tyrosine kinase inhibitor

  2018cites this paper
• Immunotherapy and pancreatic cancer: unique challenges and potential opportunities

  2018cites this paper
• New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer

  2018cites this paper
• P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.

  2018cites this paper
• Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options

  2018cites this paper
• Experimental models of pancreatic cancer desmoplasia

  2018cites this paper
• Soluble stroma‐related biomarkers of pancreatic cancer

  2018cites this paper
• Hif1α Deletion Limits Tissue Regeneration via Aberrant B Cell Accumulation in Experimental Pancreatitis.

  2018cites this paper
• Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma

  2018cites this paper
• A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib

  2018cites this paper
• Is it time for a new classification of mast cells? What do we know about mast cell heterogeneity?

  2018cites this paper
• Recovery of Immunoglobulin VJ Recombinations from Pancreatic Cancer Exome Files Strongly Correlates with Reduced Survival

  2018cites this paper
• Pancreatic stellate cell: Pandora's box for pancreatic disease biology

  2017cites this paper
• Inhibiting Myc and the Myc dependent inflammatory response as cancer therapies.

  2017cites this paper
• Chapter 27 – Ibrutinib

  2017cites this paper
• Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.

  2017cites this paper
• Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations

  2017cites this paper
• Targeting the stroma in pancreatic cancer.

  2017cites this paper
• Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy?

  2016cites this paper
• Preclinical Evaluation of Synergistic Drug Combinations in Acute Myeloid Leukemia

  2016cites this paper
• Monocytes promote liver carcinogenesis in an oncogene-specific manner.

  2016cites this paper
• CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.

  2016cites this paper
• Leading Edge Review The Basis of Oncoimmunology

  2016cites this paper
• Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.

  2016cites this paper
• Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth

  2016cites this paper
• Recent Advancements in Pancreatic Cancer Immunotherapy

  2016cites this paper
• Characterization and use of HapT1-derived homologous tumors as a preclinical model to evaluate therapeutic efficacy of drugs against pancreatic tumor desmoplasia

  2016cites this paper
• Clinical Insights Into the Biology and Treatment of Pancreatic Cancer.

  2016cites this paper
• Ibrutinib repurposing: from B-cell malignancies to solid tumors

  2016cites this paper
• Current management and future directions in metastatic pancreatic adenocarcinoma

  2016cites this paper
• Immune checkpoint therapy for pancreatic cancer

  2016cites this paper
• Personalized therapy for pancreatic cancer: Do we need better targets, arrows, or both?

  2016cites this paper
• An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts

  2016cites this paper